Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28645287 | 0.75 | — | — | |
| SCHEMBL28827769 | 0.68 | HSP90AA1 (0.33) | — | |
| SCHEMBL7144083 | 0.68 | NISCH (0.38) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL81650 | 0.67 | NISCH (0.59) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL28425230 | 0.65 | NISCH (0.56) | NISCHMTORADKALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL1536214 | 0.65 | NISCH (0.56) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL9026316 | 0.64 | NISCH (0.50) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL13977589 | 0.64 | NISCH (0.50) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL28540342 | 0.63 | — | — | |
| SCHEMBL87466 | 0.62 | NISCH (0.54) | NISCHMTORADKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | claimed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | claimed |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| US-6620882-B1 | Chemical intermediates for imidazoles, pyrazinones, and benzoidiazepinones; drug screening | ADVANCED SYNTECH, LLC | 2003-09-16 | — | — | US | disclosed |
| WO-2001083575-A1 | A NOVEL SOLID SUPPORT TEMPLATE FOR PREPARATION OF HIGHLY FUNCTIONALIZED HETEROCYCLE COMPOUNDS | ADVANCED SYNTECH, LLC A KENTUCKY LIMITED LIABILITY CORPORATION (US) | 2001-11-08 | — | — | WO | disclosed |
| US-4352817-A | ANTIDOTE FOR TRANQUILLIZING EFFECTS OF 1,4-BENZODIAZEPINES | HOFFMANN-LA ROCHE INC. (US) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | NISCH 1815/4885MTOR 564/4885ADK 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.